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Since November 2012, there has been an increase in 
reported cases of hepatitis A in tourists returning from 
Egypt in several European countries. As of 24 April, 
80 HAV cases in travellers with symptom onset after 
1 November 2012 visiting different areas in Egypt have 
been reported. Four cases from Norway, six cases from 
the Netherlands and five cases from England share an 
identical hepatitis A viral RNA sequence. This increase 
in cases suggests that vaccination recommendations 
for travellers to hepatitis A endemic countries should 
be reinforced.
The alert
Since January 2013, six hepatitis A cases with travel 
history to Egypt during the incubation period (2–6 
weeks after infection) were reported to the Norwegian 
Surveillance System for Communicable Diseases 
(MSIS). Typically, a single case of hepatitis A with 
travel history to Egypt is reported in Norway annually. 
Four of the six cases were genotyped and were found 
to be infected with the same genotype 1B hepatitis A 
virus (HAV)-strain. On 15 April 2013, the Norwegian 
Institute of Public Health posted an urgent inquiry on 
the Epidemic Intelligence Information System (EPIS) 
platform asking if any other European countries had 
observed an increase in HAV with travel history to Egypt 
in the same period. The genome sequence (N-terminal 
VP1 and VP1/P2A) shared by the four Norwegian cases 
was also provided at this time. Initially, four coun-
tries (Denmark, Germany, Netherlands and Sweden) 
responded that they had all observed an increased 
number of hepatitis A patients with travel history 
to Egypt. On 19 April 2013, an alert was also sent 
through the European Commission Early Warning and 
Response System (EWRS). Subsequently, an increase 
in HAV cases in tourists returning to England was also 
reported. A multi-national investigation has been ini-
tiated in order to identify European Union/ European 
Economic Area (EU/EEA) countries with reported 
increases in HAV among travellers to Egypt, compare 
travel history among cases, and potentially identify 
any common exposures among travellers originating 
from different countries.
Background
The incidence of HAV in European countries has 
decreased from 15.1 in 1996 to 3.9 per 100,000 popu-
lation in 2006, attributable to improved sanitary and 
living conditions [1,2]. However, the reduction in circu-
lation of HAV has led to an increase of susceptible indi-
viduals, resulting in several outbreaks in recent years, 
notably among European tourists visiting Egypt [3-6]. 
In Egypt, the burden of disease due to HAV is one of the 
highest in the world, with most HAV strains belonging 
to genotypes 1A and 1B. Recent studies of the presence 
of HAV in sewage and in the population have shown 
that the virus circulates widely in Egypt [7]. Egypt is a 
popular destination for travellers from many European 
countries (Table 1) [8-12]. HAV vaccination is generally 
recommended for all travellers to Egypt, although fund-
ing the vaccination for tourists or including the vaccine 
as part of the national vaccination plan is uncommon. 
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Hepatitis A cases are mandatorily notifiable in all EU/
EEA countries. In Denmark, Germany, the Netherlands, 
Norway and Sweden, age, sex, vaccination status and 
location of travel is submitted as part of the notifica-
tion. In England the same information is recorded at 
notification with the exception of vaccination status 
and location of travel which is collected as part of 
local public health surveillance. In Denmark, Statens 
Serum Institut performs sequencing for surveillance 
purposes of all IgM positive samples received from 
local diagnostic laboratories. At the Norwegian and 
Dutch Institutes of Public Health samples are analysed 
for sequence comparison, on request, such as in sus-
pected outbreaks. In Sweden and Germany, genotyp-
ing is not done routinely. In England, HAV IgM positive 
serum samples are genotyped and sequenced as part 
of the enhanced surveillance programme. 
Case definition for the 
outbreak investigation
A probable case is defined as a symptomatic person 
positive for HAV IgM with onset of symptoms or test-
ing date (if date of symptom onset is unavailable) after 
1 November 2012 and with travel history to Egypt two 
to six weeks before onset of symptoms/date of testing 
(if date of symptom onset is unavailable) and with no 
other known hepatitis A exposure.
 A confirmed case is defined as a probable case with 
RNA sequence matching the Norwegian outbreak 
sequence. HAV cases are excluded if they are a differ-
ent genotype or have a different sequence to the out-
break strain. Probable cases that are found to have a 
different genotype or a different sequence are being 
excluded at this time.
Description of cases
As of 24 April, 80 HAV cases in travellers with symp-
tom onset after 1 November 2012 visiting different 
areas in Egypt have been reported (Table 2). Overall, 
46%* of cases are male, and the ages of cases range 
from three to 76 years (Table 3). Onset of symptoms of 
HAV cases ranged from week 44 of 2012 (29 October 
to 4 November) to Week 15 of 2013 (8 April to 14 April) 
(Figure). Cases occurred in several waves, with a peak 
in Week 6 (4 February to 10 February). Cases from 
England, the Netherlands and Norway sharing the out-
break strain are clustered between Week 5 and Week 
13. Cases travelled primarily to Sharm-El-Sheik and 
Hurghada (Table 4), with cases linked by genotyping 
reporting travel history to both Sharm-El-Sheik and 
Hurghada.
Table 1
Information on travel to Egypt for Denmark, England, 
Germany, the Netherlands, Norway and Sweden
Country Information on travel to Egypt
Denmark Unavailable
England
The estimated number of annual visits to Egypt 
by residents of England (on average between 
2008 and 2012) is approximately 540,000. 
However, the number of visits to Egypt has been 
decreasing over the last four years (367,793 in 
2012 compared to 673,227 in 2009).
Germany
According to the National Statistics Office 
in Germany, 1,275,872 persons travelled by 
air between Germany and Egypt from March 
2012 through February 2013 (most recent data 
available).
Netherlands
Data from the Central Bureau of Statistics in the 
Netherlands indicates that the number of visits 
to Egypt has remained relatively stable over 
the last five years, with approximately 1%, or 
approximately 241,000, of all documented travels 
going to Egypt annually.
Norway
The Norwegian Embassy in Egypt estimates that 
approximately 40,000 Norwegians visit Egypt 
annually.
Sweden
According to the Swedish Travel and Tourist 
database an average number of 170,236 persons 
travelled annually to Egypt from Sweden during 
the last four years. The number for 2012 was 
178,362 persons.
Table 2
Hepatitis A cases in travellers to Egypt from Denmark, England, Germany, the Netherlands, Norway and Sweden with 
symptom onset datea after 01 November 2012 as of 24 April 2013 (n=80)
Country of origin Total number of  outbreak cases
Number of  
probable cases
Number of  
confirmed cases
Mean number of  
cases in the same period 
2007–2012
Denmark 7 7 0 1.2
England 11 6 5 2.2
Germany 39 39 0 10
Netherlands 11 5 6 2.2
Norway 6 2 4 1.4
Sweden 6 6 0 1.8
Total 80 65 15 –
a Date of testing was used when date of symptom onset was unavailable.
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Interviews of Norwegian and Danish cases
In Norway, all six cases have been interviewed using a 
short questionnaire designed to collect information on 
clinical information, travel history and places of food 
consumption. Five cases travelled to Sharm-El-Sheik 
with the same travel company, but stayed in two dif-
ferent hotels; the sixth case travelled to Hurghada with 
a different company. Four of the cases have been hos-
pitalised. In Denmark, five of seven cases have been 
interviewed using a similar questionnaire to that used 
in Norway. Three travelled to Sharm-El-Sheik with the 
same travel company and stayed at the same hotel. One 
case also travelled to Sharm-El-Sheik and stayed at a 
different hotel. One case travelled to Hurghada with 
a third company. All cases from Norway and Denmark 
stayed at hotels that were all-inclusive or had on-site 
restaurants, and all cases reported eating exclusively 
or almost exclusively from the hotel facilities. A multi-
national investigation on common exposures among 
the reported cases from all countries, including hotels, 
airlines, organised tours and food items, is currently 
being considered.
Table 3
Sex and age of hepatitis A cases related to Egypt travel 
from Denmark, England, Germany, the Netherlands, 
Norway and Sweden with symptom onset datea after 01 
November 2012 as of 24 April 2013 (n=80)*
Country  
of origin
Median age  
(range)
Proportion  
of males (%)
Denmark 28 (10–57) 6/7 (86)
England 30 (4–56) 4/11 (36)
Germany 48 (4–76) 19/39 (49)
Netherlands 38 (21–59) 3/11 (27)
Norway 56 (22–63) 2/6 (33)
Sweden 17 (3–75) 3/6 (50)
a  Date of testing was used when date of symptom onset was 
unavailable.
Figure
Distribution of probable and confirmed hepatitis A cases with travel history to Egypt, by country of origin and week of 
symptom onset after 01 November 2012 as of 24 April 2013
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Only 78 of the total 80 cases are represented on the figure as symptom onset date was only available for 37 of 39 German cases.
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Laboratory investigations
The genome sequence (N-terminal VP1 and VP1/P2A) of 
HAV from four of the six Norwegian cases was identi-
cal (HAV genotype 1B); the remaining cases have not 
yet been sequenced. The outbreak sequence (provided 
at the end of the article), has been submitted to the 
Foodborne Viruses in Europe network (FBVE network), 
and is being submitted to Genbank. The Netherlands 
has acquired sequence data from six cases, of which 
all share an identical RNA sequence in the overlap-
ping region of 440 nucleotides in the VP1/P2A region 
with the outbreak strain. England has identified iden-
tical sequences to those reported by Norway in five 
laboratory-confirmed cases. Denmark and England 
have excluded two and four cases, respectively, based 
on genotyping, which are not presented here, includ-
ing several 1B HAV strains in cases with travel history 
to Egypt during the outbreak period. In Sweden and 
Germany, genotyping is being considered.  
The Nordic countries, Germany, the Netherlands and 
England have relatively few cases of HAV reported 
annually. If an increase in cases is detected in several 
countries simultaneously, genotyping and sequenc-
ing potentially enables linking of cases internation-
ally. However, many countries do not routinely type 
to this level, which may explain why so few countries 
have reported an increase following the messages sent 
through EPIS and EWRS. The response from specific 
countries in this outbreak may also have been attribut-
able to the heightened awareness due to the concur-
rent outbreak of HAV in Nordic countries [13]. The initial 
response from the represented countries may also 
reflect travel patterns in people from colder climates 
during the winter months.
Vaccination recommendations
Despite the explicit vaccination recommendations in 
all involved countries for travellers to Egypt, almost 
no cases were vaccinated prior to travel. In Denmark, 
England, the Netherlands, Norway and Sweden all 
cases with known vaccination status were unvac-
cinated. In Germany one case reported full course of 
vaccination and is being interpreted as a vaccination 
failure. All other cases from Germany with available 
information were unvaccinated. This increase in cases 
reported from European travellers returning from 
Egypt suggests that European public health authori-
ties should consider reinforcing HAV vaccine recom-
mendations for tourists travelling to endemic areas, 
especially Egypt. Although HAV vaccination is recom-
mended, with the exception of England, none of the 
involved countries fund the vaccination of tourists or 
include the vaccine as part of the national vaccination 
plan. In England the hepatitis A vaccine is often pro-
vided free of charge by general practitioners.
The lack of vaccination may be partly explained by the 
perception among travellers that the risk of acquiring 
hepatitis A is low when engaging in organised holi-
days or activities. All interviewed cases in Norway and 
Denmark stayed in hotels that were either all-inclusive 
or had restaurants on-site. Information regarding par-
ticipation of HAV cases in specific activities such as 
cruises, day trips, organised tours and recreational 
activities that may present a risk of exposure is una-
vailable at this time. Public health authorities may wish 
to engage travel companies in order to ensure travel-
lers are informed about vaccination requirements prior 
to travel. Because of the increasing number of travel-
lers booking tickets online, an automated reminder 
Table 4
Location of travel in Egypt of total hepatitis A cases from Denmark, England, Germany, the Netherlands, Norway and 
Sweden with symptom onset datea 01 November 2012 as of 24 April 2013 (n=80)
Country of origin
Location of travel in Egypt
Number of cases (number of confirmed outbreak cases)
Sharm-El-Sheik Hurghada Marsa Alam Cairo Multiple locations Unknown
Denmark 3 (0) 1 (0) 0 (0) 0 (0) 1 (0)b 2 (0)
England 6 (4) 2 (1) 0 (0) 1 (0) 1 (0)c 1 (0)
Germany 2 (0) 12 (0) 1 (0) 2 (0) 2 (0)d 20 (0)
Netherlands 2 (0) 3 (3) 0 (0) 0 (0) 0 (0) 6 (3)
Norway 5 (4) 1 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Sweden 2 (0) 1 (0) 0 (0) 0 (0) 0 (0) 3 (0)
Total 20 (8) 20 (4) 1 (0) 3 (0) 4 (0) 32 (3)
Percentage of all cases 25 25 1 3 4 40
a  Date of testing was used when date of symptom onset was unavailable.
b  The case went on a Nile cruise and to Sharm-El-Sheik.
c  The case took part in a Red Sea cruise and traveled to Sharm-El-Sheik.
d  One case participated in a Nile cruise, the other case went on a Nile Cruise, to Hurghada and to Cairo.
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when booking tickets has also been suggested as a 
means of increasing vaccination coverage [14]. Further 
investigation into the level of knowledge and attitudes 
among tourists visiting countries where hepatitis A is 
prevalent, particularly those joining chartered tours, 
could assist in targeting information about HAV vac-
cination. The collection of this information is being 
planned as part of the next stage of the multi-national 
investigation.
Conclusions
This investigation into an outbreak of cases of hepatitis 
A in tourists to Egypt from several EU/EEA countries is 
ongoing and at this time the dynamics of the increase 
in cases are unclear. Although the background level 
in Egypt of the HAV strain involved in this outbreak is 
unknown at this time, a unique sequence among cases 
may indicate a common exposure. This hypothesis is 
potentially reinforced as confirmed cases appear to be 
temporally clustered between Week 5 and Week 10 of 
2013. As of 25 April 2013 a total of 13 countries have 
responded to the EPIS urgent inquiry that they have at 
least one case which may match the probable case def-
inition and are being investigated. The authors would 
like to invite other countries that have experienced an 
increase in hepatitis A in tourists returning from Egypt, 
or that have detected the sequences reported here, to 
share their data with the outbreak team. The National 
Institute for Public Health and the Environment in the 
Netherlands (RIVM) and Norwegian Institute of Public 
Health (depending on capacity) offer their sequence 
facilities to countries where sequencing is not among 
routine procedures. Please be aware that an actual rise 
may only be noted through typing. Sequences can be 
shared and compared in an international HAV database 
prepared by RIVM, for which access can be obtained by 
contacting fbve@rivm.nl.
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*Authors’ correction: 
The value of 46% in the sentence ‘Overall, 46% of cases are 
male, and the ages of cases range from three to 76 years 
(Table 3)’ was erroneously written as 49% in the original 
publication. In addition in Table 3, for England, the values 
of 4/11 for the proportion of males, and 36 for the respective 
percentage were originally 7/11 and 64. These mistakes were 
corrected on 26 April 2013.
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